Key points are not available for this paper at this time.
Merck & Co. has agreed to buy the ophthalmology firm EyeBio for 1. 3 billion up front and up to 1. 7 billion in milestone payments. Once the deal closes, Merck will inherit a trispecific antibody called Restoret, which EyeBio is developing as a treatment for vision loss caused by diabetic macular edema and neovascular age-related macular degeneration. Restoret is in early-stage human trials.
Rowan Walrath (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: